BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its inventory of finished peramivir for addition to the U.S. Centers for Disease Control and Prevention (CDC) Strategic National Stockpile. This inventory is sufficient for the treatment of approximately one thousand patients and will be delivered in the event that the government so instructs. Intravenous (i.v.) peramivir is currently undergoing a pre-emergency use authorization (EUA) review. Government agencies are considering the future option of providing peramivir through an EUA in the event of a severe influenza outbreak with significant hospitalizations. BioCryst is advancing the clinical development of peramivir under terms of a $102.6 million, four-year contract from the HHS.
"BioCryst is working diligently with government agencies to provide i.v. peramivir as a treatment option for an influenza emergency," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "With its parenteral route of administration, peramivir has the potential to help patients who may have difficulty with an oral or inhaled anti-viral medication. In addition, BioCryst is in negotiations with the Division of Microbiology and Infectious Diseases (DMID) and the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) to conduct a study of peramivir in a pediatric patient population."
The clinical activity of peramivir has previously been demonstrated in various clinical studies. The sensitivity of the swine flu virus to peramivir has recently been reported by the CDC (1). Ten of the thirteen isol
|SOURCE BioCryst Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved